Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Obstet Gynaecol ; 36(3): 399-402, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26470829

RESUMO

Pentraxin-3 (PTX3) plays an important role in the primary inflammatory response. We aim to evaluate PTX3 as a diagnostic marker of ovarian torsion in an experimental rat model. In this study, 16 female Sprague Dawley albino mature rats were randomly allocated to Group 1 (control, sham operated) and Group 2 (experimental ovarian torsion model). A torsion model was set up using atraumatic vascular clips just above and below the right ovary for a 3-h ischaemia. Blood samples were collected before and three hours after ovarian torsion. Three hours after ovarian torsion, right ovary was surgically removed for histopathological examination in both groups. There was no significant difference in preoperative PTX3 level in both groups (1.05 ± 0.20 ng/mL vs 1.09 ± 0.28 ng/mL, p > 0.05). Three hours after the operation, mean plasma level of PTX3 was significantly higher in ovarian torsion group than the control group (2.13 ± 0.49 ng/mL vs 1.07 ± 0.22 ng/mL, p = 0.001). Also, the mean total histopathological score was significantly increased in the torsion group. PTX3 can be used in clinical practice as a useful marker for early diagnosis of ovarian torsion.


Assuntos
Proteína C-Reativa/metabolismo , Doenças Ovarianas/sangue , Componente Amiloide P Sérico/metabolismo , Anormalidade Torcional/sangue , Animais , Biomarcadores/sangue , Modelos Animais de Doenças , Feminino , Doenças Ovarianas/diagnóstico , Doenças Ovarianas/patologia , Ovário/patologia , Distribuição Aleatória , Ratos Sprague-Dawley , Anormalidade Torcional/diagnóstico , Anormalidade Torcional/patologia
2.
Clin Rehabil ; 29(6): 525-37, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25142280

RESUMO

OBJECTIVE: To determine whether symptoms of urinary incontinence is reduced by pelvic floor muscle training, to determine whether urinary incontinence can be totally eliminated by strengthening the pelvic floor muscle to grade 5 on the Oxford scale. DESIGN: Prospective randomized controlled clinical trial. SETTING: Outpatient urogynecology department. SUBJECTS: One hundred thirty cases with stress and mixed urinary incontinence. INTERVENTION: All participants were randomly allocated to the pelvic floor muscle training group or control group. A 12-week home based exercise program, prescribed individually, was performed by the pelvic floor muscle training group. MAIN MEASURES: Urinary incontinence symptoms (Incontinence Impact Questionnaire-7, Urogenital Distress Inventory-6, bladder diary, stop test and pad test) were assessed, and the pelvic floor muscle strength was measured for (PERFECT testing, perineometric and ultrasound) all participants before and after 12 weeks of treatment. RESULTS: The pelvic floor muscle training group had significant improvement in their symptoms of urinary incontinence (P=0.001) and an increase in pelvic floor muscle strength (P=0.001, by the dependent t test) compared with the control group. All the symptoms of urinary incontinence were significantly decreased in the patients that had reached pelvic floor muscle strength of grade 5 and continued the pelvic floor muscle training (P<0.05). CONCLUSION: The study demonstrated that pelvic floor muscle training is effective in reducing the symptoms of stress and mixed urinary incontinence and in increasing pelvic floor muscle strength.


Assuntos
Terapia por Exercício , Diafragma da Pelve , Incontinência Urinária/terapia , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Método Simples-Cego , Avaliação de Sintomas , Resultado do Tratamento
3.
Int J Oral Maxillofac Surg ; 42(2): 249-55, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23078753

RESUMO

This study evaluates bone quality in sinus augmented with autogenous bone with or without platelet rich plasma (PRP) mix. 15 partially edentulous patients requiring maxillary sinus floor augmentation, followed by implant insertion were studied. In group I, 5 patients underwent maxillary sinus lifting with autogenous bone augmentation and implant insertion at 6 months post grafting. In group II, 10 patients underwent maxillary sinus lifting with autogenous bone augmentation mixed with PRP prepared from the patient's own blood with implant insertion at 4 or 6 months post grafting (n=5 for each implantation time). A core biopsy was taken at the time of implant placement for histological and histomorphometric evaluation. Immediately and 3 months after implantation, group I showed the statistically significant highest mean bone density (p=0.046 and 0.022, respectively). At 6 months post-implantation, Group II showed the statistically significant highest mean bone density (p=0.041). Histomorphometric analysis showed that group I had the statistically significant highest mean value (39.5±7.4; p=0.003). Enrichment with PRP did not significantly improve bone density or morphometric value at 3 months post grafting. PRP enriched bone grafts were associated with superior bone density at 6 months post grafting.


Assuntos
Regeneração Óssea/efeitos dos fármacos , Fator de Crescimento Derivado de Plaquetas/farmacologia , Plasma Rico em Plaquetas , Levantamento do Assoalho do Seio Maxilar/métodos , Adulto , Análise de Variância , Densidade Óssea/efeitos dos fármacos , Transplante Ósseo , Implantação Dentária Endóssea , Feminino , Seguimentos , Regeneração Tecidual Guiada Periodontal , Humanos , Masculino , Pessoa de Meia-Idade , Estatísticas não Paramétricas , Resultado do Tratamento , Adulto Jovem
4.
Clin Exp Obstet Gynecol ; 37(3): 237-9, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21077536

RESUMO

A 32-year-old female with a clinical history of abdominal swelling underwent CT of the abdomen. A huge biloculated cystic mass with a mural nodule in the abdominal and pelvic region was seen. The lesion showed slightly homogeneous enhancement. The imaging findings suggested an ovarian tumor. Histopathological evaluation after surgical resection revealed that the lesion was a bilateral ovarian endometriosis.


Assuntos
Endometriose/diagnóstico por imagem , Doenças Ovarianas/diagnóstico por imagem , Adulto , Diagnóstico Diferencial , Endometriose/cirurgia , Feminino , Humanos , Doenças Ovarianas/cirurgia , Neoplasias Ovarianas/diagnóstico , Tomografia Computadorizada por Raios X
5.
Int J Gynecol Cancer ; 16(4): 1552-6, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16884364

RESUMO

The objective of this study was to investigate the effect of arsenic trioxide (As(2)O(3)) on topoisomerase II levels using western blotting method on MDAH 2774 ovarian carcinoma cell culture. Experimental designs were established to determine the cytotoxic effects of As(2)O(3) on MDAH 2774 cells and the IC50 (fatal dose for the 50% of cells) value. Cytotoxicity experiments were carried out using various concentrations of As(2)O(3). The 2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) and trypan blue dye-exclusion tests were used to evaluate cytotoxicity. Topoisomerase II expressions were investigated using western blotting method with various concentrations of As(2)O(3). Densitometric analysis of topoisomerase 2 bands was carried out using Quantity One 1-D analysis software (Bio-Rad USA, Life Science Research, Hercules, CA). IC50 value of As(2)O(3) was found to be 5 x 10(-6) M for MDAH 2774 cells. When the bands were evaluated, it was observed that there was a decrease in topoisomerase II levels in MDAH 2774 cells with increasing concentrations of As(2)O(3). It was also observed by the densitometric analysis that topoisomerase II expression ratios of MDAH 2774 cells were decreased by approximately 50% at this concentration. Topoisomerase II levels were significantly decreased with the increasing concentrations of As(2)O(3). Inhibition of topoisomerase II enzyme was one of the antiproliferative influence mechanisms of As(2)O(3).


Assuntos
Antineoplásicos/toxicidade , Proliferação de Células/efeitos dos fármacos , DNA Topoisomerases Tipo II/metabolismo , Neoplasias Ovarianas/tratamento farmacológico , Óxidos/toxicidade , Trióxido de Arsênio , Arsenicais , Western Blotting , Regulação para Baixo , Feminino , Inibidores do Crescimento/toxicidade , Humanos , Neoplasias Ovarianas/enzimologia , Neoplasias Ovarianas/patologia , Células Tumorais Cultivadas/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...